MS
MRNA icon

Maven Securities’s Moderna MRNA Stock Holding History

Maven Securities’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-21,400
Closed -$2.21M – 1111
2023
Q3 		$2.21M Buy
21,400
+12,400
+138% +$1.38M 0.03% 377
2023
Q2 		$1.09M Sell
9,000
-9,600
-52% -$1.28M 0.02% 420
2023
Q1 		$2.86M Buy
18,600
+11,300
+155% +$1.86M 0.06% 222
2022
Q4 		$1.31M Sell
7,300
-10,800
-60% -$1.77M 0.03% 355
2022
Q3 		$2.14M Buy
18,100
+8,100
+81% +$1.23M 0.04% 300
2022
Q2 		$1.43M Sell
10,000
-1,100
-10% -$157K 0.04% 284
2022
Q1 		$1.91M Buy
11,100
+1,200
+12% +$202K 0.07% 194
2021
Q4 		$2.51M Sell
9,900
-2,300
-19% -$672K 0.07% 157
2021
Q3 		$4.73M Buy
12,200
+2,800
+30% +$1.03M 0.15% 97
2021
Q2 		$2.21M Buy
9,400
+6,500
+224% +$1.16M 0.09% 208
2021
Q1 		$380K Buy
+2,900
New +$420K 0.02% 750

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Maven Securities's MRNA Position: Q4 2023 in Review

Maven Securities sold out of Moderna (MRNA) in Q4 2023, closing a stake of 5,769 shares — an estimated $596K sold.

Maven Securities first reported a position in MRNA in Q3 2019 and held it in 8 quarters. The position peaked at $1.53M in Q3 2022. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Maven Securities reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Maven Securities sold 5,769 Moderna shares in Q4 2023, an estimated $596K.
  • Maven Securities first reported a position in Moderna in Q3 2019 and held it in 8 quarters.
  • Maven Securities's Moderna position peaked at $1.53M in Q3 2022.
  • 884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Maven Securities's 13F filing for Q4 2023, filed 12 Feb 2024.